Binod Dhakal

404 total citations
27 papers, 191 citations indexed

About

Binod Dhakal is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Binod Dhakal has authored 27 papers receiving a total of 191 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 16 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Binod Dhakal's work include Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (12 papers) and Protein Degradation and Inhibitors (9 papers). Binod Dhakal is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), CAR-T cell therapy research (12 papers) and Protein Degradation and Inhibitors (9 papers). Binod Dhakal collaborates with scholars based in United States, Australia and Spain. Binod Dhakal's co-authors include Saurabh Chhabra, Parameswaran Hari, Susan Bal, Kelly Godby, Timothy M. Schmidt, Anita D’Souza, Rebecca Silbermann, Bhagirathbhai Dholaria, Natalie S. Callander and Eva Medvedova and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Binod Dhakal

22 papers receiving 186 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Binod Dhakal United States	6	130	123	113	44	16	27	191
Tonia Nesheiwat United States	9	153 1.2×	75 0.6×	110 1.0×	37 0.8×	9 0.6×	22	195
Omar Castañeda Puglianini United States	9	122 0.9×	88 0.7×	88 0.8×	25 0.6×	21 1.3×	30	194
Hairong Lyu China	7	85 0.7×	65 0.5×	119 1.1×	29 0.7×	18 1.1×	21	234
Yunsi Olyslager United States	8	153 1.2×	108 0.9×	100 0.9×	28 0.6×	4 0.3×	14	180
Myrna Nahas United States	7	80 0.6×	46 0.4×	60 0.5×	61 1.4×	13 0.8×	33	146
Luzalba Sanoja-Flores Spain	6	47 0.4×	55 0.4×	65 0.6×	38 0.9×	15 0.9×	12	131
Amanda R. Leonti United States	8	55 0.4×	113 0.9×	99 0.9×	35 0.8×	36 2.3×	32	193
Xugeng Wang China	4	107 0.8×	64 0.5×	59 0.5×	46 1.0×	5 0.3×	5	141
Soley Thordardottir Netherlands	9	138 1.1×	51 0.4×	70 0.6×	183 4.2×	10 0.6×	10	271
Y. Xu China	5	50 0.4×	82 0.7×	87 0.8×	11 0.3×	16 1.0×	17	137

Countries citing papers authored by Binod Dhakal

Since Specialization

Citations

This map shows the geographic impact of Binod Dhakal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binod Dhakal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binod Dhakal more than expected).

Fields of papers citing papers by Binod Dhakal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binod Dhakal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binod Dhakal. The network helps show where Binod Dhakal may publish in the future.

Co-authorship network of co-authors of Binod Dhakal

This figure shows the co-authorship network connecting the top 25 collaborators of Binod Dhakal. A scholar is included among the top collaborators of Binod Dhakal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binod Dhakal. Binod Dhakal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sidana, Surbhi, Joaquín Martínez‐López, Albert Oriol, et al.. (2025). POSTER: MM-1070 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses. Clinical Lymphoma Myeloma & Leukemia. 25. S307–S307.

Richard, Shambavi, Mahmoud Gaballa, Tara Gregory, et al.. (2025). Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study. Blood. 146(Supplement 1). 269–269.

Ailawadhi, Sikander, Larry D. Anderson, Binod Dhakal, et al.. (2025). Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clinical Lymphoma Myeloma & Leukemia. 26(2). 85–93.

Voorhees, Peter M., Tom Martin, Yi Lin, et al.. (2025). Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 43(16_suppl). 7507–7507. 1 indexed citations

Akhtar, Othman Salim, Kwang Woo Ahn, Anita D’Souza, et al.. (2024). Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(12). 1191.e1–1191.e8. 1 indexed citations

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients. Clinical Lymphoma Myeloma & Leukemia. 24. S237–S237. 2 indexed citations

Dhakal, Binod, Hang Quach, Andrew Spencer, et al.. (2024). Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3364–3364. 1 indexed citations

Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157. 2 indexed citations

Bishop, Michael R., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up. Blood. 144(Supplement 1). 4825–4825. 4 indexed citations

10.

Dhakal, Binod, Andrew J. Yee, Paul G. Richardson, et al.. (2024). Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3366–3366. 4 indexed citations

11.

Abid, Muhammad Bilal, Anikó Szabó, Timothy S. Fenske, et al.. (2024). Infectious Complications in Patients with Hematologic Malignancies Receiving CD19 Vs. BCMA Targeted CAR-T Therapy. Transplantation and Cellular Therapy. 30(2). S210–S211.

12.

Silbermann, Rebecca, Timothy M. Schmidt, Susan Bal, et al.. (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation. SHILAP Revista de lepidopterología. 4(3). 775–778. 2 indexed citations

13.

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901. 71 indexed citations

14.

Kazandjian, Dickran, Hang Quach, Hanlon Sia, et al.. (2023). Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM). Blood. 142(Supplement 1). 4707–4707. 5 indexed citations

15.

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2023). Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients. Blood. 142(Supplement 1). 1023–1023. 5 indexed citations

16.

Quach, Hang, Andrew Spencer, Michael Löw, et al.. (2022). Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study. Blood. 140(Supplement 1). 7269–7271. 3 indexed citations

17.

Sia, Hanlon, Joshua Richter, Tara Cochrane, et al.. (2022). A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 140(Supplement 1). 10182–10184. 3 indexed citations

18.

Pasquini, Marcelo C., Saurabh Chhabra, Sabarinath Venniyil Radhakrishnan, et al.. (2022). Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 140(Supplement 1). 7215–7216. 2 indexed citations

19.

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2022). Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma. Blood. 140(Supplement 1). 7439–7440. 8 indexed citations

20.

Hadidi, Samer Al, Anikó Szabó, Sabarinath Venniyil Radhakrishnan, et al.. (2022). Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy. Blood. 140(Supplement 1). 8038–8039. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact